|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
![]() |
![]() |
||||||||||||
![]() |
|||||||||||||
|
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
MicroTransponder is developing the SAINT™ System*, a wireless neurostimulation technology platform to
treat neurological disease. The SAINT™ is a minimally invasive device that does not require implanted batteries or wires.
It is significantly smaller than current neurostimulation devices. The initial therapeutic area for the SAINT™ will be treatment
for chronic pain. However, the dynamic team of neuroscientists and medical device engineers at MicroTransponder is developing the SAINT™
for a pipeline of additional indications based on Vagus Nerve Stimulation, including stroke rehabilitation, tinnitus, and anxiety.
MicroTransponder has a substantial neurostimulation focused R&D program which includes an initiative to use the SAINT™
to assist the delivery of chemotherapy treatments for glioblastoma and other cancer therapeutics. |
|
Latest News05/24/10 02/24/10 04/22/09
Congressional Video CEO Will Rosellini testifies before U.S. House of Representatives concerning Neurotechnology |